ReviewDrugs2023

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

Nanthini Jayabalan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.